We serve 9′-phenyl-9H,9’H-2,3′-bicarbazole CAS:1345202-03-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Contact us for information like 9′-phenyl-9H,9’H-2,3′-bicarbazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,23-PDC physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,23-PDC Use and application,9-phenyl-2,3′-bi-9H-carbazole technical grade,usp/ep/jp grade.
Related News: ICIG has agreed to offer employment to the unit’s approximately 120 employees upon closing, and plans to maintain operations at its primary location, a manufacturing facility in Liestal, Switzerland.(3R,4S)-3-Hydroxy-4-phenylazetidin-2-one manufacturer ICIG has agreed to offer employment to the unit’s approximately 120 employees upon closing, and plans to maintain operations at its primary location, a manufacturing facility in Liestal, Switzerland.1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine,hydrochloride supplier Ten domestic API leading enterprises of CSPC, Puluo Pharmaceutical, Huahai Pharmaceutical, Chuang Nuo Pharmaceutical, Federal Pharmaceuticals, Zhejiang Pharmaceutical, Yifan Pharmaceutical, Jiangxi Tianxin, Zhejiang Chemical Industry, and Xinhua Pharmaceutical rank among China’s API exporters The top ten in the list.3-(S)-(1-Cyano-1,1-diphenylmethyl)-1-tosylpyrrolidine vendor Ten domestic API leading enterprises of CSPC, Puluo Pharmaceutical, Huahai Pharmaceutical, Chuang Nuo Pharmaceutical, Federal Pharmaceuticals, Zhejiang Pharmaceutical, Yifan Pharmaceutical, Jiangxi Tianxin, Zhejiang Chemical Industry, and Xinhua Pharmaceutical rank among China’s API exporters The top ten in the list.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.
